3SBio (TRSBF) Short-Term Debt : $296 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is 3SBio Short-Term Debt?

3SBio's Short-Term Debt for the quarter that ended in Dec. 2023 was $296 Mil.

3SBio's quarterly Short-Term Debt increased from Dec. 2022 ($59 Mil) to Jun. 2023 ($279 Mil) and increased from Jun. 2023 ($279 Mil) to Dec. 2023 ($296 Mil).

3SBio's annual Short-Term Debt increased from Dec. 2021 ($24 Mil) to Dec. 2022 ($59 Mil) and increased from Dec. 2022 ($59 Mil) to Dec. 2023 ($296 Mil).

3SBio Short-Term Debt Historical Data

The historical data trend for 3SBio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Short-Term Debt Chart

3SBio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

69.00

55.08

23.58

59.28

295.73

3SBio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															23.58	37.37	59.28	279.03	295.73

3SBio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

3SBio Short-Term Debt Related Terms

Thank you for viewing the detailed overview of 3SBio's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio (TRSBF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

01530:Hong Kong 83B:Germany

Address

No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027

Website

https://www.3sbio.com

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (TRSBF) Headlines

No Headlines